BRIEF published on 11/10/2025 at 21:55, 24 days 8 hours ago Integrated BioPharma Reports Financial Results for Q3 2025 Financial Results Net Income Revenue Decline Operating Income Contract Manufacturing
PRESS RELEASE published on 11/10/2025 at 21:50, 24 days 8 hours ago Integrated BioPharma Reports Results for Its Quarter Ended September 30, 2025 Integrated BioPharma, Inc. reports financial results for the quarter ended September 30, 2025, with $12.7 million revenue and insights on operating income and net income Financial Results Revenue Net Income Operating Income Integrated BioPharma
BRIEF published on 09/23/2025 at 21:45, 2 months 11 days ago Integrated BioPharma Reports Fiscal Year 2025 Results Financial Results Revenue Growth Net Income Operating Income Contract Manufacturing
PRESS RELEASE published on 09/23/2025 at 21:40, 2 months 11 days ago Integrated BioPharma Reports Results for its Quarter and Fiscal Year Ended June 30, 2025 Integrated BioPharma, Inc. reports 11.8% increase in revenue for Q2 2025. Operating income rises in Q2 & FY 2025. Net loss in Q2 but net income grows for FY 2025 Revenue Increase Net Income Net Loss Operating Income Integrated BioPharma
BRIEF published on 05/14/2025 at 21:35, 6 months 21 days ago Integrated BioPharma, Inc. Posts Financial Results for Q1 2025 Financial Results Revenue Growth Operating Income Q1 2025 Key Customers
PRESS RELEASE published on 05/14/2025 at 21:30, 6 months 21 days ago Integrated BioPharma Reports Results for its Quarter Ended March 31, 2025 Integrated BioPharma, Inc. reports a 6.1% revenue increase for Q1 2025 compared to Q1 2024. Company had operating income and net income growth. Key focus on core business and expanding customer base Financial Results Revenue Increase Net Income Operating Income Integrated BioPharma
BRIEF published on 02/13/2025 at 22:00, 9 months 19 days ago Integrated BioPharma Reports Quarterly Results with Increased Revenue Revenue Growth Q4 Results Operating Income Customer Base Expansion Integrated BioPharma
PRESS RELEASE published on 02/13/2025 at 21:55, 9 months 19 days ago Integrated BioPharma Reports Results for its Quarter Ended December 31, 2024 Integrated BioPharma, Inc. reports 9.6% increase in revenue to $12.6 million for quarter ended Dec 31, 2024. Operating income of $0.2 million. Detailed financial results provided Financial Results Revenue Increase Quarterly Report Operating Income Integrated BioPharma
BRIEF published on 11/13/2024 at 23:38, 1 year ago Integrated BioPharma, Inc. Announces Q3 2024 Financial Results Revenue Growth Net Income Integrated BioPharma Customer Diversification Q3 2024 Results
PRESS RELEASE published on 11/13/2024 at 23:33, 1 year ago Integrated BioPharma Reports Results for its Quarter Ended September 30, 2024 Integrated BioPharma, Inc. reports revenue growth in Q3 2024 with net income of $0.3 million. Diversification of customer base leads to increased financial performance Revenue Growth Financial Performance Diversification Q3 2024 Integrated BioPharma
Published on 12/05/2025 at 02:35, 3 hours 41 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 5 hours 16 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 7 hours 11 minutes ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 7 hours 16 minutes ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 03:30, 2 hours 46 minutes ago CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 6 hours 25 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 9 hours 51 minutes ago Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 10 hours 1 minute ago Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 19:10, 11 hours 6 minutes ago SCHOTT Pharma’s preliminary results for fiscal year 2025; outlook for FY 2026 and update of mid-term guidance
Published on 12/04/2025 at 18:00, 12 hours 16 minutes ago Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 12 hours 31 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 12 hours 32 minutes ago Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 23 hours 15 minutes ago bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
Published on 12/03/2025 at 18:00, 1 day 12 hours ago Declaration of voting rights at the end of November 2025
